호흡 보조 기기 시장 : 제공 형태, 장비 유형, 환자 인터페이스, 용도, 의료 현장, 환자 연령층, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Respiratory Assist Devices Market is projected to grow by USD 37.17 billion at a CAGR of 7.06% by 2032.

Respiratory Assist Devices Market Executive Summary

Respiratory assist devices are central to modern respiratory care, spanning non-invasive ventilation, invasive ventilators, CPAP and BiPAP systems, oxygen concentrators, humidifiers, airway clearance systems, and connected monitoring accessories. Demand is anchored by a substantial disease burden: the World Health Organization identifies chronic obstructive pulmonary disease as a leading global cause of death, with 3.23 million deaths reported in 2019, while asthma, pneumonia, sleep-disordered breathing, and acute respiratory failure continue to increase the need for timely respiratory support.

The market is moving from hospital-centered critical care toward a broader continuum that includes emergency transport, long-term care, and home respiratory therapy. Aging populations, higher survival rates among patients with chronic cardiopulmonary disease, and the post-pandemic emphasis on oxygen availability, ventilator readiness, and non-invasive respiratory support are increasing procurement attention across health systems, payers, and homecare providers.

Transformative Shifts Reshaping Respiratory Care

The respiratory assist devices landscape is being reshaped by three structural shifts: care decentralization, device connectivity, and supply chain resilience. Hospitals continue to require advanced ventilators and high-flow oxygen support, but payers and clinicians are increasingly prioritizing home-based CPAP, BiPAP, portable oxygen concentrators, and remote monitoring to reduce avoidable readmissions and support chronic respiratory disease management.

Regulatory and procurement priorities are also changing. The COVID-19 response exposed vulnerabilities in oxygen infrastructure, ventilator availability, and component sourcing, prompting governments and providers to diversify suppliers, strengthen service networks, and validate device performance under emergency-use and routine-care conditions. Manufacturers that combine clinical reliability, interoperability, cybersecurity readiness, and lifecycle service support are best positioned for sustained adoption.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing respiratory assist devices through smarter pressure titration, leak detection, predictive alarms, patient adherence analytics, and clinical decision support. In sleep therapy, algorithmic adjustment of airway pressure can improve comfort and adherence, while connected platforms help clinicians identify residual apnea events, mask fit issues, and therapy gaps without requiring frequent in-person visits.

In acute and critical care, AI-enabled analytics can support earlier detection of patient-ventilator asynchrony, deterioration risk, and weaning readiness. These applications do not replace clinical judgment, but they can reduce alarm fatigue, improve workflow efficiency, and enable more personalized respiratory support when validated with high-quality clinical data, cybersecurity controls, bias monitoring, and transparent performance governance.

Key Regional Insights for Respiratory Assist Devices

Asia-Pacific is a high-priority region for respiratory assist devices because of large patient populations, urban air pollution exposure, rising healthcare access, and expanding domestic manufacturing in China, India, Japan, South Korea, and Australia. The WHO has consistently linked air pollution exposure with respiratory and cardiovascular morbidity, reinforcing demand for oxygen therapy, non-invasive ventilation, and long-term respiratory care. North America remains a technology-intensive region, supported by established reimbursement pathways, high diagnostic awareness for obstructive sleep apnea, strong homecare networks, and sustained demand for connected respiratory monitoring.

Latin America is expanding through public hospital upgrades, private provider investment, and broader adoption of oxygen therapy in Brazil and Mexico, particularly for chronic respiratory disease and acute care readiness. Europe benefits from advanced clinical guidelines, a strong home respiratory care base, mature sleep medicine pathways, and procurement focus on energy efficiency, patient safety, and regulatory compliance. The Middle East is investing in tertiary care capacity, intensive care infrastructure, and medical tourism-linked specialty services, while Africa's opportunity is closely tied to oxygen access, affordability, biomedical engineering capacity, local maintenance models, and reliable power supply for respiratory support systems.

Key Group Insights Across Economic and Policy Blocs

ASEAN markets are advancing through hospital modernization, growing private healthcare networks, urban pollution-related respiratory needs, and increasing demand for portable oxygen and non-invasive ventilation in major metropolitan centers. GCC countries are prioritizing advanced hospital infrastructure, intensive care capacity, premium homecare services, and digital health integration aligned with national healthcare transformation programs and broader investment in specialized care delivery.

The European Union emphasizes harmonized medical device regulation, clinical evidence, traceability, and post-market surveillance under the MDR framework, creating a premium for compliant and well-documented respiratory technologies. BRICS markets combine large respiratory disease burdens, air quality challenges, expanding healthcare access, and manufacturing ambitions, while the G7 leads in connected care adoption, reimbursement sophistication, clinical research capacity, and high-acuity respiratory innovation. NATO-aligned procurement considerations increasingly emphasize emergency preparedness, supply continuity, deployable respiratory support, and resilient medical logistics for crisis response.

Key Country Insights for Priority Markets

The United States leads in connected sleep therapy, home oxygen services, and advanced ICU ventilation, supported by strong clinical infrastructure, FDA oversight, established durable medical equipment channels, and high awareness of sleep-disordered breathing. Canada prioritizes equitable access, provincial procurement efficiency, and remote care delivery across dispersed populations, while Mexico and Brazil show rising demand through hospital expansion, private healthcare investment, and chronic respiratory disease management. In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize guideline-led respiratory care, home ventilation programs, sleep apnea treatment pathways, and compliance with EU or UK medical device requirements, while Russia maintains demand for critical care technologies and domestically supported supply chains.

China and India are scale markets shaped by large populations, air quality concerns, expanding hospital networks, and growing domestic production of oxygen and ventilation technologies. Japan and South Korea support high-quality respiratory care through aging-population needs, advanced electronics ecosystems, strong hospital capabilities, and established standards for device quality and patient safety. Australia combines mature reimbursement, rural and remote care challenges, and demand for reliable portable oxygen concentrators, CPAP systems, and non-invasive ventilation devices that support home-based respiratory therapy.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated connectivity, serviceability, and patient-centered design. Devices that reduce setup complexity, improve comfort, limit noise, enhance portability, and provide actionable adherence or ventilation data can strengthen outcomes for providers and homecare organizations while supporting payer expectations for measurable value.

Manufacturers should also diversify component sourcing, invest in regional service hubs, strengthen biomedical engineering training, and align product portfolios with local oxygen infrastructure realities. Strategic partnerships with hospitals, sleep labs, distributors, emergency preparedness agencies, and digital health platforms can accelerate adoption, but success will depend on cybersecurity, regulatory readiness, transparent AI validation, usability testing, and robust post-market surveillance.

Research Methodology

This executive summary is developed through a structured secondary and primary research approach aligned with evidence-based market intelligence practices. Secondary inputs include public health data from recognized authorities such as the WHO, CDC, FDA, EMA, national health agencies, peer-reviewed literature, medical device regulations, clinical guidelines, reimbursement references, adverse event databases, and publicly available industry disclosures.

Primary validation typically incorporates expert interviews across manufacturers, distributors, clinicians, respiratory therapists, biomedical engineers, procurement leaders, and homecare service providers. Findings are triangulated across disease burden, technology adoption, regulatory pathways, installed base indicators, supply chain signals, clinical use cases, and regional healthcare investment to produce evidence-led interpretation without relying on market sizing, market share, or forecasting.

Conclusion

The respiratory assist devices market is entering a more connected, resilient, and patient-centric phase. Adoption is supported by chronic respiratory disease prevalence, aging demographics, sleep apnea diagnosis, emergency preparedness, oxygen infrastructure investment, and the expansion of home-based respiratory care.

Competitive advantage will increasingly depend on validated clinical performance, reliable supply, digital interoperability, AI governance, cybersecurity, usability, and strong service infrastructure. Companies that combine high-acuity innovation with affordable, scalable respiratory support solutions will be best positioned to meet global healthcare needs across hospitals, emergency settings, long-term care, and home therapy environments.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Respiratory Assist Devices Market, by Offering

• 7.1. Positive Airway Pressure (PAP) Devices
  • 7.1.1. Continuous Positive Airway Pressure (CPAP) Devices
  • 7.1.2. Automatic Positive Airway Pressure (APAP) Devices
  • 7.1.3. Bilevel Positive Airway Pressure (BiPAP) Devices
• 7.2. Ventilators
• 7.3. Mask & Interfaces
  • 7.3.1. Nasal Masks
  • 7.3.2. Full Face Masks
• 7.4. Resuscitation Devices
• 7.5. Airway Clearance Assist Devices
• 7.6. Solutions
  • 7.6.1. Remote Monitoring
  • 7.6.2. Data Management
• 7.7. Services
  • 7.7.1. Maintenance & Support
  • 7.7.2. Calibration

8. Respiratory Assist Devices Market, by Device Type

• 8.1. Stationary
• 8.2. Tabletop
• 8.3. Portable

9. Respiratory Assist Devices Market, by Patient Interface

• 9.1. Nasal Interfaces
• 9.2. Oral Interfaces
• 9.3. Invasive Airway Interfaces
  • 9.3.1. Endotracheal Tube
  • 9.3.2. Tracheostomy Tube

10. Respiratory Assist Devices Market, by Application

• 10.1. Chronic Obstructive Pulmonary Disease (COPD)
• 10.2. Emergency & Trauma Care
• 10.3. Sleep Apnea Therapy
  • 10.3.1. Central Sleep Apnea
  • 10.3.2. Obstructive Sleep Apnea
• 10.4. Respiratory Failure
  • 10.4.1. Acute
  • 10.4.2. Chronic
• 10.5. Neonatal Respiratory Disorders

11. Respiratory Assist Devices Market, by Care Setting

• 11.1. Hospitals
• 11.2. Specialty Clinics
• 11.3. Home Healthcare
• 11.4. Ambulatory Care Centers

12. Respiratory Assist Devices Market, by Patient Age Group

• 12.1. Pediatric
• 12.2. Adult
• 12.3. Geriatric
• 12.4. Neonatal
• 12.5. Infant

13. Respiratory Assist Devices Market, by Distribution Channel

• 13.1. Offline Sales
• 13.2. Online Sales
  • 13.2.1. Manufacturer Websites
  • 13.2.2. eCommerce Platforms

14. Respiratory Assist Devices Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Respiratory Assist Devices Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Respiratory Assist Devices Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. ResMed Inc.
• 18.2. Fisher & Paykel Healthcare Limited
• 18.3. Koninklijke Philips N.V.
• 18.4. Getinge AB
• 18.5. Dragerwerk AG & Co. KGaA
• 18.6. GE HealthCare Technologies Inc.
• 18.7. Medtronic plc
• 18.8. Hamilton Medical AG
• 18.9. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
• 18.10. Inogen Inc.
• 18.11. Baxter International Inc.
• 18.12. Drive DeVilbiss Healthcare Ltd.
• 18.13. PARI GmbH
• 18.14. Lowenstein Medical SE & Co. KG
• 18.15. React Health
• 18.16. AdaptHealth, LLC
• 18.17. Air Liquide S.A.
• 18.18. AirLife
• 18.19. Apex Medical Devices
• 18.20. BMC Medical Co. Ltd.
• 18.21. Breas Medical AB
• 18.22. Cardinal Health, Inc.
• 18.23. Masimo Corporation
• 18.24. Medline Industries, LP
• 18.25. Natus Medical Incorporated
• 18.26. Nihon Kohden Corporation
• 18.27. OMRON Healthcare, Inc.
• 18.28. Schiller AG
• 18.29. Shenyang Canta Medical Tech Co., Ltd.
• 18.30. Smiths Group plc
• 18.31. TE Connectivity plc
• 18.32. Teijin Limited
• 18.33. Teleflex Incorporated
• 18.34. ZOLL Medical Corporation